Jonathan C. Javitt M.D., M.P.H.
Net Worth
Last updated:
What is Jonathan C. Javitt M.D., M.P.H. net worth?
The estimated net worth of Dr. Jonathan C. Javitt M.D., M.P.H. is at least $4,743,424 as of 7 Dec 2022. He owns shares worth $1,117,124 as insider, has earned $800,000 from insider trading and has received compensation worth at least $2,826,300 in NRx Pharmaceuticals, Inc. and NRx Pharmaceuticals, Inc..
What is the salary of Jonathan C. Javitt M.D., M.P.H.?
Dr. Jonathan C. Javitt M.D., M.P.H. salary is $471,050 per year as Co-Founder, Chairman & Chief Executive Officer in NRx Pharmaceuticals, Inc.. He also receives $471,050 as Co-Founder, Chairman & Chief Executive Officer in NRx Pharmaceuticals, Inc..
How old is Jonathan C. Javitt M.D., M.P.H.?
Dr. Jonathan C. Javitt M.D., M.P.H. is 68 years old, born in 1957.
What stocks does Jonathan C. Javitt M.D., M.P.H. currently own?
As insider, Dr. Jonathan C. Javitt M.D., M.P.H. owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXPW) | Co-Founder, Chairman & Chief Executive Officer | 12,899,997 | $0.07 | $903,000 |
| NRx Pharmaceuticals, Inc. (NRXP) | Co-Founder, Chairman & Chief Executive Officer | 84,634 | $2.53 | $214,124 |
What does NRx Pharmaceuticals, Inc. do?
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
What does NRx Pharmaceuticals, Inc. do?
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Jonathan C. Javitt M.D., M.P.H. insider trading
NRx Pharmaceuticals, Inc.
Dr. Jonathan C. Javitt M.D., M.P.H. has made only one insider trade in 2022, according to the Form 4 filled with the SEC. He sold 400,000 units of NRXPW stock worth $400,000 on 7 Dec 2022.
As of 7 Dec 2022 he still owns at least 12,899,997 units of NRXPW stock.
NRx Pharmaceuticals, Inc.
Dr. Jonathan C. Javitt M.D., M.P.H. has made only one insider trade between 2022-2024, according to the Form 4 filled with the SEC. He purchased 40,000 units of NRXP stock worth $46,800 on 17 Dec 2024.
As of 7 Dec 2022 he still owns at least 84,634 units of NRXP stock.
NRx Pharmaceuticals key executives
NRx Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Jonathan C. Javitt M.D., M.P.H. (68) Co-Founder, Chairman & Chief Executive Officer
- Mr. Robert Besthof M.I.M. (59) Head of Operations & Chief Commercial Officer and Patient Officer